References
[1]. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
[2]. Sagnelli, E., Macera, M., Russo, A., Coppola, N., & Sagnelli, C. (2020). Epidemiological and etiological variations in hepatocellular carcinoma. Infection, 48(1), 7-17.
[3]. Balogh, J., Victor III, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., ... & Monsour Jr, H. P. (2016). Hepatocellular carcinoma: a review. Journal of hepatocellular carcinoma, 41-53.
[4]. Liu, Y., Yang, S., Zhou, Q., Zhou, J., Li, J., Ma, Y., ... & Zhao, Y. (2022). Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy. Nanoscale Advances, 4(22), 4847-4862.
[5]. Motola-Kuba, D., Zamora-Valdés, D., Uribe, M., & Méndez-Sánchez, N. (2006). Hepatocellular carcinoma. An overview. Annals of hepatology, 5(1), 16-24.
[6]. Befeler, A. S., & Di Bisceglie, A. M. (2002). Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 122(6), 1609-1619.
[7]. Wu, J., & Nyborg, W. L. (2008). Ultrasound, cavitation bubbles and their interaction with cells. Advanced drug delivery reviews, 60(10), 1103-1116.
[8]. Wu, P., Wang, X., Lin, W., & Bai, L. (2022). Acoustic characterization of cavitation intensity: A review. Ultrasonics Sonochemistry, 82, 105878.
[9]. Zhou Q, Wang Y, Cheng Q, et al. Graphene Oxide Modified Microbubble for the Ultrasonic Imaging and Treatment of Hepatocellular Carcinoma [J]. ACS Applied Nano Materials, 2025, 8(15): 7825-7839.
[10]. Rinaldi L, Folliero V, Palomba L, et al. Sonoporation by microbubbles as gene therapy approach against liver cancer [J]. Oncotarget, 2018, 9(63): 32182.
[11]. Meng M, Gao J, Wu C, et al. Doxorubicin nanobubble for combining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor [J]. Tumor Biology, 2016, 37(7): 8673-8680.
[12]. Tian Y, Liu Z, Zhang L, et al. Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro [J]. OncoTargets and therapy, 2018: 4785-4795.
[13]. Schroeder, Avi, Joseph Kost, and Yechezkel Barenholz. "Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes." Chemistry and physics of lipids 162.1-2 (2009): 1-16.
[14]. Blume, Alfred. "A comparative study of the phase transitions of phospholipid bilayers and monolayers." Biochimica et Biophysica Acta (BBA)-Biomembranes 557.1 (1979): 32-44.
[15]. Mukherjee, Biswajit, et al. "Size dependent variations of phospholipid based vesicular drug carriers in systemic drug activity." Current Pharmaceutical Biotechnology 16.4 (2015): 380-391.
[16]. Tikhonova, Elena G., et al. "Study of Physico-Chemical Properties and Morphology of Phospholipid Composition of Indomethacin." Nanomaterials 12.15 (2022): 2553.
[17]. Oda Y, Suzuki R, Mori T, et al. Development of fluorous lipid-based nanobubbles for efficiently containing perfluoropropane [J]. International Journal of Pharmaceutics, 2015, 487(1-2): 64-71.
[18]. Moghadam F F. Using nanoparticles in medicine for liver cancer imaging [J]. Oman medical journal, 2017, 32(4): 269.
[19]. Gong Y, Wang Z, Dong G, et al. Low-intensity focused ultrasound mediated localized drug delivery for liver tumors in rabbits [J]. Drug delivery, 2016, 23(7): 2280-2289.
[20]. Min H S, Son S, Lee T W, et al. Liver‐specific and echogenic hyaluronic acid nanoparticles facilitating liver cancer discrimination [J]. Advanced Functional Materials, 2013, 23(44): 5518-5529.